BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 12663770)

  • 1. Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice.
    Ohlschläger P; Osen W; Dell K; Faath S; Garcea RL; Jochmus I; Müller M; Pawlita M; Schäfer K; Sehr P; Staib C; Sutter G; Gissmann L
    J Virol; 2003 Apr; 77(8):4635-45. PubMed ID: 12663770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention.
    Wakabayashi MT; Da Silva DM; Potkul RK; Kast WM
    Intervirology; 2002; 45(4-6):300-7. PubMed ID: 12566713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parenteral and oral immunization with a plasmid DNA expressing the human papillomavirus 16-L1 gene induces systemic and mucosal antibodies and cytotoxic T lymphocyte responses.
    Rocha-Zavaleta L; Alejandre JE; Garcia-Carranca A
    J Med Virol; 2002 Jan; 66(1):86-95. PubMed ID: 11748663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides.
    Zwaveling S; Ferreira Mota SC; Nouta J; Johnson M; Lipford GB; Offringa R; van der Burg SH; Melief CJ
    J Immunol; 2002 Jul; 169(1):350-8. PubMed ID: 12077264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human papillomavirus type 16 L1E7 chimeric capsomeres have prophylactic and therapeutic efficacy against papillomavirus in mice.
    Bian T; Wang Y; Lu Z; Ye Z; Zhao L; Ren J; Zhang H; Ruan L; Tian H
    Mol Cancer Ther; 2008 May; 7(5):1329-35. PubMed ID: 18483320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice.
    Revaz V; Benyacoub J; Kast WM; Schiller JT; De Grandi P; Nardelli-Haefliger D
    Virology; 2001 Jan; 279(1):354-60. PubMed ID: 11145916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-helper epitopes identified within the E6 transforming protein of cervical cancer-associated human papillomavirus type 16.
    Azoury-Ziadeh R; Herd K; Fernando GJ; Frazer IH; Tindle RW
    Viral Immunol; 1999; 12(4):297-312. PubMed ID: 10630789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway.
    Peng S; Frazer IH; Fernando GJ; Zhou J
    Virology; 1998 Jan; 240(1):147-57. PubMed ID: 9448699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxic-T-lymphocyte human papillomavirus type 16 E5 peptide with CpG-oligodeoxynucleotide can eliminate tumor growth in C57BL/6 mice.
    Chen YF; Lin CW; Tsao YP; Chen SL
    J Virol; 2004 Feb; 78(3):1333-43. PubMed ID: 14722288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunization with Human Papillomavirus 16 L1+E2 Chimeric Capsomers Elicits Cellular Immune Response and Antitumor Activity in a Mouse Model.
    López-Toledo G; Schädlich L; Alonso-Castro ÁJ; Monroy-García A; García-Rocha R; Guido MC; Gissmann L; García-Carrancá A
    Viral Immunol; 2016 Jun; 29(5):276-87. PubMed ID: 27058179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficiency of HPV 16 L1/E7 DNA immunization: influence of cellular localization and capsid assembly.
    Kuck D; Leder C; Kern A; Müller M; Piuko K; Gissmann L; Kleinschmidt JA
    Vaccine; 2006 Apr; 24(15):2952-65. PubMed ID: 16414157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model.
    Greenstone HL; Nieland JD; de Visser KE; De Bruijn ML; Kirnbauer R; Roden RB; Lowy DR; Kast WM; Schiller JT
    Proc Natl Acad Sci U S A; 1998 Feb; 95(4):1800-5. PubMed ID: 9465097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Papillomavirus-like particle vaccines.
    Schiller JT; Lowy DR
    J Natl Cancer Inst Monogr; 2001; (28):50-4. PubMed ID: 11158207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes.
    Dupuy C; Buzoni-Gatel D; Touzé A; Bout D; Coursaget P
    J Virol; 1999 Nov; 73(11):9063-71. PubMed ID: 10516012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal immunization with human papillomavirus type 16 capsomeres in the presence of non-toxic cholera toxin-based adjuvants elicits increased vaginal immunoglobulin levels.
    Dell K; Koesters R; Linnebacher M; Klein C; Gissmann L
    Vaccine; 2006 Mar; 24(13):2238-47. PubMed ID: 16455165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies.
    Kawana K; Kawana Y; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
    Vaccine; 2001 Jan; 19(11-12):1496-502. PubMed ID: 11163673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization against human papillomavirus infection and associated neoplasia.
    Osen W; Jochmus I; Müller M; Gissmann L
    J Clin Virol; 2000 Oct; 19(1-2):75-8. PubMed ID: 11091150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral immunization with different assembly forms of the HPV 16 major capsid protein L1 induces neutralizing antibodies and cytotoxic T-lymphocytes.
    Thönes N; Müller M
    Virology; 2007 Dec; 369(2):375-88. PubMed ID: 17822733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells.
    Feltkamp MC; Smits HL; Vierboom MP; Minnaar RP; de Jongh BM; Drijfhout JW; ter Schegget J; Melief CJ; Kast WM
    Eur J Immunol; 1993 Sep; 23(9):2242-9. PubMed ID: 7690326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined prophylactic and therapeutic intranasal vaccination against human papillomavirus type-16 using different adeno-associated virus serotype vectors.
    Nieto K; Kern A; Leuchs B; Gissmann L; Müller M; Kleinschmidt JA
    Antivir Ther; 2009; 14(8):1125-37. PubMed ID: 20032542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.